TY - JOUR
T1 - Genetics in the endocrine system
T2 - the impact of the TRK family
AU - Hutchens, Troy
AU - Mansour, Mena
N1 - Publisher Copyright:
© 2022
PY - 2022/7
Y1 - 2022/7
N2 - Rearrangements in NTRK are rare actionable oncologic drivers in thyroid carcinoma. Although they only represent a small subset of most thyroid carcinoma subtypes, their identification remains important due to the availability of targeted therapy. Trk inhibitors are currently FDA-approved for NTRK-rearranged cancers independent of primary site and represent a crucial additional therapeutic option for patients with advanced or aggressive thyroid cancer. In the thyroid, NTRK-rearranged cancers have been shown to involve all NTRK family members (NTRK1, NTRK2, and NTRK3) as well as a multitude of different partner genes. Due to their rarity and relatively diverse molecular classification, the clinical and histologic characterization of NTRK-rearranged thyroid carcinoma remains challenging and is not currently well-defined. Given the relatively good prognosis of most thyroid carcinomas, the practical identification of NTRK-rearranged thyroid carcinomas for targeted therapy is case-specific and only considered when current therapeutic options have been exhausted.
AB - Rearrangements in NTRK are rare actionable oncologic drivers in thyroid carcinoma. Although they only represent a small subset of most thyroid carcinoma subtypes, their identification remains important due to the availability of targeted therapy. Trk inhibitors are currently FDA-approved for NTRK-rearranged cancers independent of primary site and represent a crucial additional therapeutic option for patients with advanced or aggressive thyroid cancer. In the thyroid, NTRK-rearranged cancers have been shown to involve all NTRK family members (NTRK1, NTRK2, and NTRK3) as well as a multitude of different partner genes. Due to their rarity and relatively diverse molecular classification, the clinical and histologic characterization of NTRK-rearranged thyroid carcinoma remains challenging and is not currently well-defined. Given the relatively good prognosis of most thyroid carcinomas, the practical identification of NTRK-rearranged thyroid carcinomas for targeted therapy is case-specific and only considered when current therapeutic options have been exhausted.
KW - NTRK
KW - PTC
KW - Papillary thyroid carcinoma
KW - Trk
KW - thyroid
UR - http://www.scopus.com/inward/record.url?scp=85130962073&partnerID=8YFLogxK
U2 - 10.1016/j.mpdhp.2022.05.001
DO - 10.1016/j.mpdhp.2022.05.001
M3 - Review article
AN - SCOPUS:85130962073
SN - 1756-2317
VL - 28
SP - 313
EP - 320
JO - Diagnostic Histopathology
JF - Diagnostic Histopathology
IS - 7
ER -